Help Build an A.I. Model to Predict Myasthenia Gravis Symptom Patterns and Flares

NCT ID: NCT04590716

Last Updated: 2021-07-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

113 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-10-02

Study Completion Date

2021-07-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There are limited objective measurements of MG symptoms as well as a dearth of data at a granular level of MG (myasthenia gravis) symptoms and triggers occurring longitudinally.

This study is designed to use the strengths of mobile smartphones which enable participant-driven real time capture of data manually and through augmented sensors such as video and audio, in order to better characterize MG symptoms and flares.

The study aims to enroll approximately 200 participants for approximately 9 months until analyzable data is available from at least 100 participants. Participants will complete in-app surveys for 3 months with, audiovisual recording of symptoms. This will take approximately 35 minutes per week after the initial survey.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Using their smartphones, potential participants will download the doc.ai research mobile app. There will be a web pre-screening link where potential participants will self-screen to see if they meet the basic eligibility criteria for this study. The recruitment tool for this trial is developed for diversity, fairness, and inclusion. With the aim to ensure diversity in the demographics of the trial to better understand the health needs of different populations. So, while some interested potential participants do qualify, they may not be invited into the trial due to these diversity requirements.

Patients with myasthenia gravis (MG) who meet the inclusion criteria will be invited to join this digital health trial. Participants will sign the e-consent and self-enroll into the study. Once their eligibility is confirmed by the study team (to ensure eligibility criteria and validity of participant i.e. eliminate robo sign-ins) they will be asked to take a selfie, provide documented proof of MG diagnosis, respond to a series of survey questions regarding their demographics, current health, medical history, and other MG related information.

Enrolled participants will have a daily brief check-in, 2 weekly check-ins and a weekly check-in which will include an audiovisual check-in, and will maintain an audiovisual diary to keep track of their symptoms, connect data, record their voice (to detect vocal symptoms: weakness, nasality) and take videos of their face (to detect facial symptoms: ocular, mouth droop) on a daily to weekly basis through the various data collecting modules in the doc.ai research app for the duration of their study participation. doc.ai's digital health trial platform will be leveraged to collect this data.

The study aims to enroll approximately 200 participants in approximately 9 months. It is expected that a minimum of 100 participants will be included in the final analysis as at any given time there will be a lag between potential participants expressing interest in the study, their eligibility being assessed by the PI, and participants completing all required study procedures.

At the end of their participation, participants will be asked to complete a questionnaire. After the participant has completed their final survey, they will be able to connect to a link redeemable as an Amazon.com gift card worth $250. All participants will also receive an end-of-trial-summary of the data that they had collected during the study. No medical advice or direction will be given based on this study.

In addition, in the final survey participants will be asked if they would be willing to complete a usability interview after their participation in this trial has ended. This subset of participants invited to be part of a follow-up usability interview will include those who complete all study required procedures and some who may not have completed all study required procedures, in order to assess usability experience of the app for the duration of their participation. Participants will be contacted at their end of their period of participation until a total of 10-15 participants successfully complete the usability interview. Participants who successfully complete the usability interview will receive a link for a $50 in Amazon.com gift card via the app.

For this study the data and, audio and video recordings will be captured directly on the doc.ai research app and securely stored on a HIPAA compliant cloud provider (Google Cloud Platform).

This data will be used to understand the patterns of symptoms and triggers in order to better characterize factors such as the length and timing of flares and any unique symptom patterns in order to create more objective measures of MG symptoms. Ultimately this data would be used to build a machine learning model that could predict MG symptom flares.

Primary Objective:

Use a collection of digital health modules on the smartphone to collect myasthenia gravis (MG) symptoms and triggers to better characterize symptom patterns and flares.

Secondary Objective:

Use the data collected to develop an A.I. model to detect and/or predict symptom flares.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myasthenia Gravis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Data Collection

This is a non-interventional study conducted on the participant's smartphones to record MG related symptoms and conditions.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Must have a documented diagnosis of Myasthenia Gravis
2. Must have ocular (eye drooping) and/or bulbar (speech) symptoms
3. Must be over the age of 18
4. Must reside in the US for the duration of the study
5. Must be able to read, understand, and write in English
6. Must have a smartphone supported by the doc.ai research app (iOS and Android)

Exclusion Criteria

None
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

UCB Biopharma SRL

INDUSTRY

Sponsor Role collaborator

doc.ai inc

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Doc.Ai Mobile Based

Palo Alto, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Kent RD, Kent JF, Rosenbek JC. Maximum performance tests of speech production. J Speech Hear Disord. 1987 Nov;52(4):367-87. doi: 10.1044/jshd.5204.367.

Reference Type RESULT
PMID: 3312817 (View on PubMed)

Konopka BM, Lwow F, Owczarz M, Laczmanski L. Exploratory data analysis of a clinical study group: Development of a procedure for exploring multidimensional data. PLoS One. 2018 Aug 23;13(8):e0201950. doi: 10.1371/journal.pone.0201950. eCollection 2018.

Reference Type RESULT
PMID: 30138442 (View on PubMed)

Zhou ZR, Wang WW, Li Y, Jin KR, Wang XY, Wang ZW, Chen YS, Wang SJ, Hu J, Zhang HN, Huang P, Zhao GZ, Chen XX, Li B, Zhang TS. In-depth mining of clinical data: the construction of clinical prediction model with R. Ann Transl Med. 2019 Dec;7(23):796. doi: 10.21037/atm.2019.08.63.

Reference Type RESULT
PMID: 32042812 (View on PubMed)

Kang H. The prevention and handling of the missing data. Korean J Anesthesiol. 2013 May;64(5):402-6. doi: 10.4097/kjae.2013.64.5.402. Epub 2013 May 24.

Reference Type RESULT
PMID: 23741561 (View on PubMed)

Borza D, Darabant AS, Danescu R. Real-Time Detection and Measurement of Eye Features from Color Images. Sensors (Basel). 2016 Jul 16;16(7):1105. doi: 10.3390/s16071105.

Reference Type RESULT
PMID: 27438838 (View on PubMed)

Hegde S, Shetty S, Rai S, Dodderi T. A Survey on Machine Learning Approaches for Automatic Detection of Voice Disorders. J Voice. 2019 Nov;33(6):947.e11-947.e33. doi: 10.1016/j.jvoice.2018.07.014. Epub 2018 Oct 11.

Reference Type RESULT
PMID: 30316551 (View on PubMed)

Duffy, JR: Motor Speech Disorders. Substrates, Differential Diagnosis and Management (1st ed). St. Louis, 1995, Mosby.

Reference Type RESULT

Duffy, JR: Motor Speech Disorders. Substrates, Differential Diagnosis and Management (2nd ed). New York, 2005, Elsevier Health Sciences.

Reference Type RESULT

T. Baltrusaitis, A. Zadeh, Y. C. Lim and L. Morency,

Reference Type RESULT

Panayotov V., Chen G., Povey D., Khudanpur S. (2015). Librispeech: an ASR corpus based on public domain audio books, in Proceedings of the ICASSP (South Brisbane, QLD:), 5206-5210

Reference Type RESULT

Steyaert S, Lootus M, Sarabu C, Framroze Z, Dickinson H, Lewis E, Steels JC, Rinaldo F. A decentralized, prospective, observational study to collect real-world data from patients with myasthenia gravis using smartphones. Front Neurol. 2023 Aug 1;14:1144183. doi: 10.3389/fneur.2023.1144183. eCollection 2023.

Reference Type DERIVED
PMID: 37588667 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Informed Consent Form

View Document

Related Links

Access external resources that provide additional context or updates about the study.

https://ghr.nlm.nih.gov/condition/myasthenia-gravis

"Myasthenia gravis - Genetics Home Reference - NIH."

https://info.soliris.net/wp-content/uploads/2017/12/Assessment_Tool_Booklet.pdf

Assessment Instruments for Patients with Myasthenia Gravis (MG)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DOC-005-2020

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Myasthenia Gravis Inebilizumab Trial
NCT04524273 ACTIVE_NOT_RECRUITING PHASE3